Atrium Therapeutics Expects Initial Proof-of-Concept Data in H2 2027
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Buenaventura Announces Third-Quarter and Nine-Month 2026 Results
M impact | EQUITY | Oct 30, 2026, 12:45 AM UTC
APR Q3 Operating Profit Rises 68.9% Year Over Year
APR reported third-quarter 2026 consolidated operating profit, up 68.9% year over year.
M impact | EQUITY | Oct 30, 2026, 12:44 AM UTC
APR Q3 Operating Profit Rises 68.9% Year on Year
APR’s third-quarter 2026 revenue rose 100.3% year on year.
M impact | EQUITY | Oct 30, 2026, 12:44 AM UTC
KPA-BM Holdings Trading Halted at 9:00 A.M.
Trading in KPA-BM Holdings was halted at 9:00 a.m. on October 30, 2026.
L impact | EQUITY | Oct 30, 2026, 12:44 AM UTC
Hyundai G.F. Holdings to Host Q3 Results Conference Call
Hyundai G.F. Holdings will host a conference call on its third-quarter results.
M impact | EQUITY | Oct 30, 2026, 12:42 AM UTC
Seatrium Contract Valued at Over S$200M
M impact | EQUITY | Oct 30, 2026, 12:39 AM UTC